1. Efficacy Criteria

1. Efficacy Criteria

① Near cure: Subjective symptoms disappear, the spleen shrinks to normal size, ascites disappears, and liver function returns to normal. Esophageal varices and portal vein diameter both show some improvement. ② Remarkable effect: Subjective symptoms disappear, ascites disappears, the spleen significantly shrinks, liver function approaches normal, and only slight or no improvement is seen in esophageal varices and portal vein diameter. ③ Effective: Only minor improvements are observed in subjective symptoms, portal hypertension signs, and liver function indicators, or one or two indicators improve while the rest remain unchanged. ④ Ineffective: No improvement is seen in any indicator, or existing improvements deteriorate rapidly; some patients die due to worsening conditions and uncontrolled complications.

Table 1: Comparison of Symptom Recovery Between Treatment and Control Groups

+:---------+:-------+:-------+:-----------:+:-----------:+:------------:+:------------:+ Symptoms | Treatment Group (n=154) | Control Group (n=60) | | Number of cases before and after treatment | | | | Group | | +-------------+-------------+--------------+--------------+ | Before treatment | After treatment | Before treatment | After treatment Abdominal | --- | Number of cases | 0 | 93 | 0 | 8 | | | | | | Ascites | | | | | | | +--------+-------------+-------------+--------------+--------------+ | | % | △0 | * 60. 38 | 0 | 13. 33 +--------+--------+-------------+-------------+--------------+--------------+ | + | Number of cases | 60 | 43 | 30 | 28 | +--------+-------------+-------------+--------------+--------------+ | | % | △38. 96 | * 27. 92 | 50.00 | 46. 67 +--------+--------+-------------+-------------+--------------+--------------+ | + + | Number of cases | 94 | 18 | 30 | 24 | +--------+-------------+-------------+--------------+--------------+ | | % | △61. 03 | * 11. 69 | 50. 00 | 40. 00 Spleen | ---- | Number of cases | 20 | 66 | 0 | 6 | | | | | | Large | | | | | | | +--------+-------------+-------------+--------------+--------------+ | | % | △12. 98 | * 42. 85 | 0 | 10. 00 +--------+--------+-------------+-------------+--------------+--------------+ | + | Number of cases | 49 | 42 | 38 | 34 | +--------+-------------+-------------+--------------+--------------+ | | % | △31.81 | * 27. 27 | 63. 33 | 56.67 +--------+--------+-------------+-------------+--------------+--------------+ | + + | Number of cases | 85 | 46 | 22 | 20 | +--------+-------------+-------------+--------------+--------------+ | | % | △55. 19 | * 29.87 | 36. 67 | 33. 23 Lower limb edema | ------ | Number of cases | 2 | 103 | 0 | 10 | +--------+-------------+-------------+--------------+--------------+ | | % | △1.29 | * 66. 88 | 0 | 16. 67 +--------+--------+-------------+-------------+--------------+--------------+ | * | Number of cases | 31 | 31 | 24 | 24 | +--------+-------------+-------------+--------------+--------------+ | | % | △20. 12 | * 20. 12 | 40. 00 | 40. 00 +--------+--------+-------------+-------------+--------------+--------------+ | + + | Number of cases | 121 | 20 | 36 | 26 | +--------+-------------+-------------+--------------+--------------+ | | % | △78. 57 | * 12. 99 | 60.00 | 43. 33 Portal | 12 | | Number of cases | 5 | 29 | 10 | 10 | | | | | | Static | | | | | | Pulse | | | | | | | | | | | | Mouth | | | | | | | | | | | | Diameter | | | | | | | +--------+-------------+-------------+--------------+--------------+ | | % | △3. 24 | * 18. 83 | 16. 67 | 16.67 +--------+--------+-------------+-------------+--------------+--------------+ | 12 | Number of cases | 73 | 87 | 26 | 32

| 〜20 | | | | | | +--------+-------------+-------------+--------------+--------------+ | | % | △47. 40 | * 56. 49 | 43. 33 | 53. 33 +--------+--------+-------------+-------------+--------------+--------------+ | 20 f | Number of cases | 76 | 38 | 24 | 18 | +--------+-------------+-------------+--------------+--------------+ | | % | △49. 35 | * 24. 68 | 40. 00 | 30. 00

<!-- translated-chunk:41/57 -->

Task output rules: Translate this markdown block from Chinese to English. Preserve markdown markers, links, and formatting. Keep headings and list structure unchanged. Return only the translated block.

Input: Abdomen | --- | Number of cases | 5 | 125 | 12 | 12 | | | | | | Water | | | | | | | +--------+-------------+-------------+--------------+--------------+ | | % | △3. 24 | * 81. 17 | 20.00 | 20. 00 +--------+--------+-------------+-------------+--------------+--------------+ | + | Number of cases | 149 | 29 | 48 | 48 | +--------+-------------+-------------+--------------+--------------+ | | % | △96. 75 | * 18. 83 | 80. 00 | 80. 00 Note: The unit for portal vein diameter is mm

△P>0.05 △Statistical analysis before treatment in the treatment and control groups

*P<0.01〜0.05 *Statistical analysis after treatment in the treatment and control groups

Table 2 Comparison of test indicators before and after treatment in the treatment and control groups

+:---------+:--------+:----:+:----------:+:----------:+:----------:+:----------:+ Physical signs | | Treatment group (n=154) | Control group (n=60) | | | Physical signs | | | | | | Number of cases before and after treatment | | | | | | Grouping | | | +------+------------+------------+------------+------------+ | Number of cases | Before treatment | After treatment | Before treatment | After treatment GPT | 25 ↓ | Number of cases | 30 | 104 | 6 | 12 | +------+------------+------------+------------+------------+ | | % | △19.48 | * 67. 53 | 10.00 | 20. 00 +---------+------+------------+------------+------------+------------+ | 25 〜50 | Number of cases | 23 | 30 | 24 | 24 | +------+------------+------------+------------+------------+ | | % | △14. 94 | * 19. 48 | 40.00 | 40. 00 +---------+------+------------+------------+------------+------------+ | 50↑ | Number of cases | 101 | 20 | 30 | 24 | +------+------------+------------+------------+------------+ | | % | △65. 58 | * 12. 99 | 50. 00 | 40. 00 TTT | 6↓ | Number of cases | 13 | 96 | 4 | 10 | +------+------------+------------+------------+------------+ | | % | △8.44 | * 62. 34 | 6. 67 | 16.67 +---------+------+------------+------------+------------+------------+ | 6〜12 | Number of cases | 79 | 32 | 26 | 24 | +------+------------+------------+------------+------------+ | | % | △51. 30 | * 20. 78 | 43. 33 | 40. 00 +---------+------+------------+------------+------------+------------+ | 12↑ | Number of cases | 62 | 26 | 30 | 26 | +------+------------+------------+------------+------------+ | | % | △40. 26 | * 16. 88 | 50.00 | 43.33 A/G | Normal | Number of cases | 7 | 82 | 4 | 8 | +------+------------+------------+------------+------------+ | | % | △4.55 | * 53. 25 | 6. 67 | 13.33 +---------+------+------------+------------+------------+------------+ | G elevated | Number of cases | 55 | 40 | 20 | 22 | +------+------------+------------+------------+------------+ | | % | △35.71 | * 25. 97 | 33. 33 | 36.37 +---------+------+------------+------------+------------+------------+ | Inversion | Number of cases | 92 | 32 | 36 | 30 | +------+------------+------------+------------+------------+ | | % | △59. 74 | * 20. 78 | 60. 00 | 50. 00 γ-Globulin | 25↓ | Number of cases | 28 | 108 | 10 | 16 | +------+------------+------------+------------+------------+ | | % | △18. 18 | * 70. 13 | 16.67 | 26. 67 +---------+------+------------+------------+------------+------------+ | 25 〜50 | Number of cases | 29 | 27 | 14 | 20 | +------+------------+------------+------------+------------+ | | % | △18. 83 | * 17. 53 | 23.33 | 33.33 +---------+------+------------+------------+------------+------------+ | 50 ↑ | Number of cases | 93 | 19 | 36 | 24 | +------+------------+------------+------------+------------+ | | % | △62.99 | * 12. 34 | 60. 00 | 40. 00 TBIL | 17 ↓ | Number of cases | 98 | 124 | 18 | 24 | +------+------------+------------+------------+------------+ | | % | △63. 64 | * 80. 52 | 30. 00 | 40. 00 +---------+------+------------+------------+------------+------------+ | 17 〜34 | Number of cases | 27 | 12 | 20 | 18 | +------+------------+------------+------------+------------+ | | % | △17. 53 | * 7.79 | 33. 33 | 30. 00 +---------+------+------------+------------+------------+------------+

| 34 ↑ | Number of cases | 29 | 18 | 22 | 18 | +------+------------+------------+------------+------------+ | | % | △18. 83 | * 11.68 | 36. 67 | 30. 00 HBsAg | --- | Number of cases | 52 | 86 | 24 | 44 | +------+------------+------------+------------+------------+ | | % | △33. 77 | * 55.847 | 40. 00 | 73. 33 +---------+------+------------+------------+------------+------------+ | + | Number of cases | 102 | 68 | 36 | 16 | +------+------------+------------+------------+------------+ | | % | △66. 23 | * 44. 16 | 60. 00 | 26.67 Note: GPT is measured using the Karmen method, TBIL unit: µmol/L △P>0.05 △Statistical analysis before treatment in the treatment and control groups *P<0.01〜0.05 *Statistical analysis after treatment in the treatment and control groups